Navigation Links
Thyroid Hormone Analogue for Treating High Cholesterol
Date:3/10/2010

An international team of investigators at Johns Hopkins Medical Institutions, the Karolinska University Hospital and Institute, and The Feinstein Institute for Medical Research tested a substance called Eprotirome in patients with high cholesterol.

Manhasset, NY (Vocus) March 10, 2010 -- An experimental thyroid drug reduces cholesterol without the troublesome side effects experienced by some people on statins, according to a study published today in The New England Journal of Medicine. An international team of investigators at Johns Hopkins Medical Institutions, the Karolinska University Hospital and Institute, and The Feinstein Institute for Medical Research (http://www.feinsteininstitute.org) tested a substance called Eprotirome in patients with high cholesterol.

Following 189 people with high cholesterol over a three-month period, they observed that it lowered cholesterol levels without the classic thyroid risks to the heart and bone. The study was supported by Karo Bio in Sweden, a company that is developing the drug for its cholesterol-lowering effects.

Over three decades, Irwin Klein, MD, an endocrinologist at the Feinstein Institute, has been at the forefront of researching the connection between thyroid and heart health. It seemed that people with underactive thyroid glands also had high cholesterol levels. These high cholesterol levels were dramatically reduced with thyroid hormone replacement. But the problem in using thyroid hormone for cholesterol lowering is the side effects of an overactive thyroid gland: people can become anxious and have heart palpitations, muscle weakness and bone thinning.

Scientists spent years trying to develop thyroid analogs that lowered lipids without unwanted side effects. American scientists, including Dr. Klein and John D. Baxter, MD, a senior member of The Methodist Hospital Research Institute, have been working with Karo Bio scientists to solve this problem. They landed on one in particular that lowered cholesterol without any of the problems with the traditional thyroid medicines. Phase I studies showed the drug safe.

In the current Phase II study, they reported that it was both safe and effective in lowering cholesterol. What is not known from this study is whether this lowering of cholesterol will ultimately protect patients from heart disease. Dr. Klein said he thinks it may work to reduce cardiovascular disease. “Every percentage that you lower cholesterol, you lower the risk for heart disease,” he said. “High cholesterol is the single most modifiable risk factor.” About one in three people have cholesterol levels that are higher than the national guidelines set by federal agencies.

Jens Kristensen, a scientist at Karo Bio and the lead author on the study, and his colleagues also found that the experimental medicine lowered a cholesterol product in the blood called lipoprotein A, which is damaging to the heart. There are no available medicines that lower lipoprotein A and Eprotirome lowered the levels by 33 percent.

Since cholesterol lowering is a surrogate marker for heart disease, the scientists will have to conduct other studies to test whether it does in fact reduce heart disease. The next phase of testing must include larger numbers of patients. If the results hold, it could ultimately be used as an alternative to statins. A small percentage of patients can’t take statins, either because they don’t work to lower cholesterol for them or they suffer from unrelenting side effects such as muscle pains, myopathy and tiredness.

About The Feinstein Institute for Medical Research
Headquartered in Manhasset, NY, The Feinstein Institute for Medical Research is home to international scientific leaders in cancer, leukemia, lymphoma, Parkinson's disease, Alzheimer’s disease, psychiatric disorders, rheumatoid arthritis, lupus, sepsis, inflammatory bowel disease, diabetes, human genetics, neuroimmunology, and medicinal chemistry. Feinstein researchers are developing new drugs and drug targets, and producing results where science meets the patient, annually enrolling some 10,000 subjects into clinical research programs.

###

Read the full story at http://www.prweb.com/releases/thyroid_heart_health/cholesterol/prweb3707304.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved

Related medicine news :

1. Thyroid Disease: The Hidden Epidemic
2. No End In Sight To The Armour Thyroid Shortage?
3. Stain repellent chemical linked to thyroid disease in adults
4. It's January...Do You Know Where Your Thyroid Is? Thyroid Awareness Month Focuses on Millions of Undiagnosed Americans with Thyroid Problems
5. Low Thyroid Levels May Up Need for Assisted Delivery
6. Pregnancy Complication May Be Linked to Thyroid Problems
7. Thyroid Cancer Higher in Volcanic Areas
8. Newly revised guidelines for managing thyroid cancer published in Thyroid journal
9. Thyroid surgery safe for older patients, study finds
10. Studies Evaluate Thyroid Treatment During Pregnancy
11. New robot-assisted surgical method found successful for treatment of thyroid cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... Valhalla, New York (PRWEB) , ... March 22, ... ... Blythedale Children’s Hospital have entered into a research collaboration to translate advances in ... with neurological impairments at Blythedale and beyond. The collaboration seeks to improve movement, vision, ...
(Date:3/22/2017)... ... March 22, 2017 , ... SNL Insurance ... to families and business owners in the greater Hampton Roads area, is embarking ... Society Relay For Life event. , Each year, hundreds of people living in ...
(Date:3/22/2017)... (PRWEB) , ... March 22, 2017 , ... Schneider Insurance ... families and business owners throughout the Yellowstone Valley region, is launching a charity event ... zoo and botanical garden in all of Montana State, and is home to a ...
(Date:3/22/2017)... (PRWEB) , ... March 22, 2017 , ... College basketball ... Self still makes time for recruiting – that is, recruiting people to be foster ... and homes to children who are in foster care due to abuse, neglect and ...
(Date:3/22/2017)... ... ... NYC Chiropractor Dr. Steven Shoshany recently helped host a seminar at his cutting ... and focused on a new protocol for treating pain. Dr. Shoshany is among the ... furthermore the first seminar in the country was hosted at his Integrated Chiropractic Practice. ...
Breaking Medicine News(10 mins):
(Date:3/22/2017)... , 22. März 2017   ... und weltweit tätige Anbieter von Produkten und ... den Erwerb von EPL Archives Inc. bekannt, ... der Kunden im kompletten Zyklus regulierter Forschung, ... von Proben, Speicherung von Dokumenten und Zusatzdienstleistungen ...
(Date:3/22/2017)... 22, 2017  Applied BioMath ( www.appliedbiomath.com ), ... research and development, today announced the latest line-up ... 2017 is a day full of presentations, posters, ... (QSP) community. The focus is to learn about ... accelerating drug research and development. The ...
(Date:3/22/2017)... March 22, 2017 National Medical Products ... received an Innovative Technology contract from Vizient, ... in the country. The contract was based on ... with expertise in this category who serve on ... Technology contracts for technologies that demonstrate an ability ...
Breaking Medicine Technology: